Commercializes proprietary, non‑antibiotic chemically‑modified tetracyclines for host‑modulatory treatment of diseases with high unmet need. Lead product is an orally administered clinical‑stage small molecule (incyclinide/CMT‑3/COL‑3) aimed at hospitalized sepsis patients at risk of septic shock, MODS and ARDS (including COVID‑19); pipeline includes preclinical analogues.